Procter & Gamble (PG) Could Be 37% Above Fair Value After New Product Launches
Recent product launches at Procter & Gamble (PG), including the Febreze x Dunkin’ scent collection and Olay’s updated Repair Serum Body Wash line, have refocused attention on how the company’s innovation pipeline might relate to its stock valuation.
Despite the product buzz, Procter & Gamble’s recent share price moves have been relatively muted. The stock is at US$146.92 after a 7 day share price return of 2.64% and a year to date share price return of 3.62%, while the 1 year total shareholder return declined 4.99%. This suggests that investors remain cautious as they weigh new product activity, margin pressures and questions around organic growth against a valuation that some see as undemanding.
Compare how Procter & Gamble’s product pipeline and valuation story stack up against a handpicked 52 high quality undervalued stocks that also pair strong brands with earnings power.
After a modest rebound in Procter & Gamble’s share price and fresh headlines around new products, the key debate is whether most of the stock’s rerating is already behind you or whether the valuation still leaves meaningful upside ahead.
Most Popular Narrative: 36.6% Overvalued
At a last close of $146.92, Procter & Gamble is priced well above the most popular narrative fair value of $107.52, which frames the stock as materially overvalued based on detailed fundamental work.
Given the maturity of the business and its historical data, I believe the company will grow it''s revenues at around ~3% and, for simplicity sake, converge to the economy growth rate ~4.69% (here I''m using the 10 Year U.S. bond rate as a proxy to it).
Want to see what really drives that $107.52 fair value for Procter & Gamble? The narrative leans heavily on modest growth, firm margins and a valuation multiple that assumes steady but unspectacular compounding. The key is how those building blocks are combined. The details are where this narrative gets interesting.
Result: Fair Value of $107.52 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Procter & Gamble faces risks that could challenge this overvaluation narrative, including competitive pressure on margins and any slowdown in its 2.67% annual revenue growth.
Find out about the key risks to this Procter & Gamble narrative.
Another View On Procter & Gamble’s Valuation
While the most popular community narrative sees Procter & Gamble as 36.6% overvalued, the SWS DCF model points in the opposite direction. It estimates fair value at $196.96 per share, which is about 25.4% above the current $146.92 price, and frames the stock as undervalued. Which set of assumptions do you find more convincing?
For a closer look at how the cash flow assumptions compare with those narrative forecasts, it is worth reviewing the full methodology behind the SWS DCF work. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Procter & Gamble for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed sentiment around Procter & Gamble has you on the fence, use the data to stress test both sides of the story and move quickly to shape your own view by weighing the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Procter & Gamble?
If Procter & Gamble has sharpened your focus on quality and valuation, now may be a good time to widen your watchlist with other focused opportunities.
- Target potential growth stories that still trade at appealing valuations by scanning the 52 high quality undervalued stocks before they gain broader attention.
- Strengthen your income stream by reviewing the 11 dividend fortresses that may offer higher yields with support from underlying business fundamentals.
- Prioritise resilience by checking the 79 resilient stocks with low risk scores that could help you stay invested with fewer balance sheet surprises.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com